University oncology researcher Alberta Armin Gamper (left) and PhD student Amirali Bukhari have discovered hopeful cancer treatment.
Most people don't die from the cancer they first discovered, but instead of those that are spreading later.
Now, it has been shown that experimental treatment on human breast cancer cells in mice carried out by scientists at the University of Alberta not only slows down and eliminates even tumors in mice, but also to reduce metastasis, or cancer spread elsewhere. the body.
In the experiment two drugs were combined to attack the integrity of cancer cells of cancer cells, reducing their ability to repair themselves and multiply, which resulted in tumor shrinkage. Both drugs are already being used, but separately, for cancer treatment.
As a result of the dose duo, an oncology assistant teacher, Armin Gamper, said that it was a “synergy” that saw the combination more successful than one of the drugs alone.
“When we treat only one drug, we find that the tumor growth slows down, and the same with the other drug. When you combine both, the tumor is shrinking… until we don't even feel it anymore, ”says Gamper in a phone interview.
Typically, the type of cell that is metastacizes is more resistant to treatment. But with the experimental drug combination, the cells spreading from the initial tumor were so sensitive to treatment with the other cancer cells.
“We have never seen that from the front,” he said.
In the experiment, the tumors returned to the mice “much later, after we gave the best to the treatment,” said Gamper. But it is explained that the laboratory mice did not have a functional immune system, and it is noted that it is likely that the remaining cancer cells would be removed by the immune system in humans.
“We hope we could get a full recovery (with this treatment),” he said.
Cancers other than breast cancer, including ovarian cancer and colon cancer, could also test candidates for the new procedure.
Of course, mice are not people. The next phase of the trial will see the drug company actively supporting a small study of suitable voluntary patients for treatment at the Cross Cross Institute. Gamper hopes the action will take place by the end of the year, followed by a large group study within two years.
Another positive result for the mice in U research is that the nasty side effects associated with traditional cancer treatments such as chemotherapy and radiation are minimized.
“We didn't see signs of diarrhea, weight loss, effect on gut lining, hair loss or behavior change.” T
Gamper said that the successful results were encouraging, because they came from “work of benches,” the laboratory experiments that are often slow and laborious with our everyday science things.
“Science can be very frustrating and most things don't work out. But then when you get a nice discovery, you reward you. ”